Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology

Chera L. Maarouf; Thomas G. Beach; Charles H. Adler; Michael Malek-Ahmadi; Tyler A. Kokjohn; Brittany N. Dugger; Douglas G. Walker; Holly A. Shill; Sandra A. Jacobson; Marwan N. Sabbagh; Alex E. Roher

doi:10.4137/BMI.S11422

Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology

Chera L. Maarouf, Thomas G. Beach, Charles H. Adler, Michael Malek-Ahmadi, Tyler A. Kokjohn, Brittany N. Dugger, Douglas G. Walker, Holly A. Shill, Sandra A. Jacobson, Marwan N. Sabbagh, Alex E. Roher

Neurology

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Identifying biomarkers that distinguish Parkinson's disease (PD) from normal control (NC) individuals has the potential to increase diagnostic sensitivity for the detection of early-stage PD. A previous proteomic study identified potential biomarkers in post- mortem ventricular cerebrospinal fluid (V-CSF) from neuropathologically diagnosed PD subjects lacking Alzheimer's disease (AD) neuropathology. In the present study, we assessed these biomarkers as well as p-tau¹⁸¹, Aβ42, and S100B by ELISA in PD (n = 43) and NC (n = 49) cases. The p-tau¹⁸¹/Aβ42 ratio and ApoA-1 showed statistically significant differences between groups. Multiple regression analysis demonstrated that p-tau¹⁸¹/Aβ42 had a significant odds ratio: OR = 1.42 (95% confidence interval [CI], 1.12-1.84), P = 0.006. Among the molecules investigated, intriguing correlations were observed that require further investigation. Our results suggest co- existent AD CSF biomarkers within the PD group notwithstanding that it was selected to minimize AD neuropathological lesions.

Original language	English (US)
Pages (from-to)	19-28
Number of pages	10
Journal	Biomarker Insights
Volume	8
DOIs	https://doi.org/10.4137/BMI.S11422
State	Published - 2013

Keywords

Apolipoprotein A-1
Biomarkers
P-tau/aβ42 ratio
Parkinson's disease
Ventricular cerebrospinal fuid

ASJC Scopus subject areas

Molecular Medicine
Pharmacology
Biochemistry, medical

Access to Document

10.4137/BMI.S11422

Cite this

Maarouf, C. L., Beach, T. G., Adler, C. H., Malek-Ahmadi, M., Kokjohn, T. A., Dugger, B. N., Walker, D. G., Shill, H. A., Jacobson, S. A., Sabbagh, M. N., & Roher, A. E. (2013). Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology. Biomarker Insights, 8, 19-28. https://doi.org/10.4137/BMI.S11422

Maarouf, CL, Beach, TG, Adler, CH, Malek-Ahmadi, M, Kokjohn, TA, Dugger, BN, Walker, DG, Shill, HA, Jacobson, SA, Sabbagh, MN & Roher, AE 2013, 'Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology', Biomarker Insights, vol. 8, pp. 19-28. https://doi.org/10.4137/BMI.S11422

@article{ca7f5a961b91406cbf2ef755b4259fad,

title = "Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology",

abstract = "Identifying biomarkers that distinguish Parkinson's disease (PD) from normal control (NC) individuals has the potential to increase diagnostic sensitivity for the detection of early-stage PD. A previous proteomic study identified potential biomarkers in post- mortem ventricular cerebrospinal fluid (V-CSF) from neuropathologically diagnosed PD subjects lacking Alzheimer's disease (AD) neuropathology. In the present study, we assessed these biomarkers as well as p-tau181, Aβ42, and S100B by ELISA in PD (n = 43) and NC (n = 49) cases. The p-tau181/Aβ42 ratio and ApoA-1 showed statistically significant differences between groups. Multiple regression analysis demonstrated that p-tau181/Aβ42 had a significant odds ratio: OR = 1.42 (95% confidence interval [CI], 1.12-1.84), P = 0.006. Among the molecules investigated, intriguing correlations were observed that require further investigation. Our results suggest co- existent AD CSF biomarkers within the PD group notwithstanding that it was selected to minimize AD neuropathological lesions.",

keywords = "Apolipoprotein A-1, Biomarkers, P-tau/aβ42 ratio, Parkinson's disease, Ventricular cerebrospinal fuid",

author = "Maarouf, {Chera L.} and Beach, {Thomas G.} and Adler, {Charles H.} and Michael Malek-Ahmadi and Kokjohn, {Tyler A.} and Dugger, {Brittany N.} and Walker, {Douglas G.} and Shill, {Holly A.} and Jacobson, {Sandra A.} and Sabbagh, {Marwan N.} and Roher, {Alex E.}",

year = "2013",

doi = "10.4137/BMI.S11422",

language = "English (US)",

volume = "8",

pages = "19--28",

journal = "Biomarker Insights",

issn = "1177-2719",

publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology

AU - Maarouf, Chera L.

AU - Beach, Thomas G.

AU - Adler, Charles H.

AU - Malek-Ahmadi, Michael

AU - Kokjohn, Tyler A.

AU - Dugger, Brittany N.

AU - Walker, Douglas G.

AU - Shill, Holly A.

AU - Jacobson, Sandra A.

AU - Sabbagh, Marwan N.

AU - Roher, Alex E.

PY - 2013

Y1 - 2013

N2 - Identifying biomarkers that distinguish Parkinson's disease (PD) from normal control (NC) individuals has the potential to increase diagnostic sensitivity for the detection of early-stage PD. A previous proteomic study identified potential biomarkers in post- mortem ventricular cerebrospinal fluid (V-CSF) from neuropathologically diagnosed PD subjects lacking Alzheimer's disease (AD) neuropathology. In the present study, we assessed these biomarkers as well as p-tau181, Aβ42, and S100B by ELISA in PD (n = 43) and NC (n = 49) cases. The p-tau181/Aβ42 ratio and ApoA-1 showed statistically significant differences between groups. Multiple regression analysis demonstrated that p-tau181/Aβ42 had a significant odds ratio: OR = 1.42 (95% confidence interval [CI], 1.12-1.84), P = 0.006. Among the molecules investigated, intriguing correlations were observed that require further investigation. Our results suggest co- existent AD CSF biomarkers within the PD group notwithstanding that it was selected to minimize AD neuropathological lesions.

AB - Identifying biomarkers that distinguish Parkinson's disease (PD) from normal control (NC) individuals has the potential to increase diagnostic sensitivity for the detection of early-stage PD. A previous proteomic study identified potential biomarkers in post- mortem ventricular cerebrospinal fluid (V-CSF) from neuropathologically diagnosed PD subjects lacking Alzheimer's disease (AD) neuropathology. In the present study, we assessed these biomarkers as well as p-tau181, Aβ42, and S100B by ELISA in PD (n = 43) and NC (n = 49) cases. The p-tau181/Aβ42 ratio and ApoA-1 showed statistically significant differences between groups. Multiple regression analysis demonstrated that p-tau181/Aβ42 had a significant odds ratio: OR = 1.42 (95% confidence interval [CI], 1.12-1.84), P = 0.006. Among the molecules investigated, intriguing correlations were observed that require further investigation. Our results suggest co- existent AD CSF biomarkers within the PD group notwithstanding that it was selected to minimize AD neuropathological lesions.

KW - Apolipoprotein A-1

KW - Biomarkers

KW - P-tau/aβ42 ratio

KW - Parkinson's disease

KW - Ventricular cerebrospinal fuid

UR - http://www.scopus.com/inward/record.url?scp=84875184178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875184178&partnerID=8YFLogxK

U2 - 10.4137/BMI.S11422

DO - 10.4137/BMI.S11422

M3 - Article

C2 - 23533154

AN - SCOPUS:84875184178

SN - 1177-2719

VL - 8

SP - 19

EP - 28

JO - Biomarker Insights

JF - Biomarker Insights

ER -

Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this